European MidPharmas: Focused and Resilient, yet Vulnerable
European MidPharmas – R&D based pharmaceutical companies with annual revenues of between EUR 50 million and 5 billion – are having to be increasingly focused and resilient to succeed and…
European MidPharmas – R&D based pharmaceutical companies with annual revenues of between EUR 50 million and 5 billion – are having to be increasingly focused and resilient to succeed and…
The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain…
Sweden’s comprehensive and high-quality system of electronic health records is increasingly in demand from international researchers in the machine learning and AI fields and is also facilitating significant breakthroughs in…
With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019 conference in Philadelphia, the HKEX’s Michael Chan outlined some of the…
Esteve has long been a family-run business, though in early 2018 the Spanish champion decided to make a daring, though calculated, move and positioned the then CCO of Lundbeck, Staffan…
Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but…
China is a hot topic in Big Pharma investor updates these days. The world’s second-largest pharmaceutical market boasts sales growth that continuously surpasses that of the US and other developed…
Hong Kong is now the world’s second largest funding hub for biotech according to Hong Kong Chief Executive Carrie Lam. During her speech at the 2nd HKEx Biotech Summit on…
In view of the manifold hurdles encountered when attempting to raise capital, Switzerland’s medium capitalized entities and SMEs have grown adept at punching well above their weight. After the giants,…
Despite the Spanish economy and pharmaceutical market’s steady growth, many local players are becoming cognizant of the limitations and risks of operating within a single market. Therefore, these small to…
Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics business registering hefty sales growth of more than EUR 350 (USD 392) million…
Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of…
See our Cookie Privacy Policy Here
